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EDITORIAL
What IJCP authors think about open access: exploring
one possible future for publishing clinical research in a
general and internal medicine journal
This editorial shares the questions that IJCP is, at
the time of this publication, asking research authors
about ‘open access’. It aims to prompt discussion
about open access, and explains some of the
challenges that switching to open access presents to
a general and internal medicine journal like IJCP. It
invites you to share your insights, using the
approaches described below. It explains how you will
be able to read the results of our research.
An important trend
Open access publishing has changed, perhaps for-
ever, the way readers access articles in some high-
quality, peer-reviewed journals.
The beneﬁts to authors are derived from removing
the ‘pay to read’ barriers that traditionally sit
between published articles and the readers who want
to read them. Arguably this gives greater exposure
for authors’ work. Replacing traditional copyright
attribution with Creative Commons-based licensing
– another component of publishing open access –
means that authors’ work is arguably more straight-
forward to re-use [for example, Figure 1 (1)]. Also,
although this is controversial, there may be a possi-
ble citation advantage (2,3).
The cost to authors, though, is real. Whereas there
are frequently no publication costs for authors who
publish in traditional subscription journals, publish-
ing in open access journals commonly involves a
mandatory publication fee. Sometimes, this fee is
paid by research funding bodies (some of which
make unrestricted access a condition of their fund-
ing), such as Wellcome Trust, US National Institutes
of Health, UK Medical Research Council and some
corporations, including pharmaceutical companies.
Other times authors pay from their own pockets.
The cost to publishers is also real. The open access
model means that publishers can no longer collect
the subscription revenues that traditionally sustain
their journals and may mean that they instead switch
to reliance on authors paying.
Equally critical, publishers who make the switch
from a subscription to an open access approach run
the serious risk of alienating their authors, who may
Figure 1 Open access logo as an example of these authors
re-using work published by the original authors using one
of the Creative Commons licenses (1)
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the costs, and who instead take their articles to dif-
ferent journals, which continue with the traditional
approach.
Hybrid: nice but (unless something
changes) suboptimal
Some journals, like IJCP, continue to offer authors a
hybrid option: open access for individual articles
within a journal where all other articles are available
via subscription. This approach was developed to
explore the possible transition between models, from
subscription to open access. While showing some
signs of success, the hybrid approach is (and may
remain) suboptimal for some research funders, and
the spectre of ‘double dipping’ raises its head (4).
Full open access: what IJCP authors
think
At the time of this publication, and for another
6 months, we will ask all authors who submit papers
to IJCP to answer two questions about open access
(Table 1). The answers to these questions will tell us
whether or not these authors believe the possible
beneﬁts of open access publishing might outweigh
the costs.
Then, using these answers, the IJCP team will con-
sider whether or not IJCP should become an open
access journal. If we decide to take this course, IJCP
would start requiring payment of open access fees
from authors for every article we agree to publish,
although we would have a fee-waiver option for cer-
tain cases. We would no longer collect subscription
revenues for the articles we publish online and these
articles would become free to read by anyone. We
would calculate our open access publication fee in
such a way as to replace our current subscription
revenue.
Discussion: letters, Twitter
We wrote this editorial to explain our approach, and
to extend discussion to a wider audience beyond those
authors who happen to submit to IJCP in the next
6 months. We encourage you to share your thoughts
and join the debate, by submitting to IJCP a ‘Letter to
the Editor’ (approximately 200 words, at our usual
submission website) explaining what you think about
open access, and⁄or the traditional subscription
model, and why. We will review all letters, as is nor-
mal, and publish in the journal those that add insight.
We also encourage those readers who are Twitterers
to discuss open access with us on Twitter: @ijcpedi-
tors. And we will also be happy to receive communi-
cations by email.
Results: to be published
By answering our questions or by joining in the con-
versation, you will be taking part in an interesting
and highly topical debate (in the publishing world,
at least), as well as playing an active role in helping
decide how IJCP approaches open access in the
future. We will aggregate and analyse the responses
that we receive from authors (Table 1), and will
share those results with you in a future editorial.
Like this editorial, we will publish the results in an
article that is free to read online. To receive this
news as soon as it is published, please register with
IJCP online to get new content alerts (5).
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Table 1 The questions that we are, at time of publication, asking all IJCP authors
to answer
Question Statement
Format for
answer
Do you agree or
disagree with this
statement
‘I would still choose to submit my work to IJCP if
IJCP in the future required all authors to pay an
open access fee for publication and then made all
its content open access and free to read online’
Yes⁄No
We welcome your general comments (e.g. you may
want to comment on what you think a suitable
open access fee might be, considering our
benchmark of $3000)
Free text
Do you agree or
disagree with this
statement
‘I would not publish my work in any open access
journal (including IJCP if IJCP required me to pay
an open access fee) because the costs to me or
my research funder would outweigh any beneﬁts’
Yes⁄No
We welcome your general comments Free text
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EDITORIAL
Silent cerebral embolism after catheter ablation
of atrial ﬁbrillation
Stroke prevention is a cornerstone of the modern
management of atrial ﬁbrillation (AF), and the
most effective way is oral anticoagulation (OAC)
(1). However, the drawback of the approach is the
need for lifelong therapy often with cumbersome
monitoring if the Vitamin K antagonist class of
drugs (e.g. warfarin) is used. Indeed, failure to cure
AF and achieve long-term rhythm control, as well
as the growing incidence of AF in the ageing popu-
lation poses a major burden to any healthcare sys-
tem (2). From this point of view, the development
and improvement of the interventional strategies to
achieve sinus rhythm control can potentially be
both cost-effective and improve patients’ quality of
life.
A number of non-pharmacological therapies has
been developed and clinically tested for rhythm con-
trol in AF. Among these, pulmonary vein catheter
ablation or isolation is currently used widely (3).
The intervention is usually performed in patients
with symptomatic paroxysmal AF, which cannot be
controlled by antiarrhythmic agents. The utility of
the catheter ablation for patients with persistent AF
or permanent AF with heart disease is less estab-
lished.
The procedure is considered as generally safe and
efﬁcient, but the long-term beneﬁts of catheter abla-
tion are still debated. Indeed, recent meta-analyses of
trials conducted in patients with AF, mostly with the
paroxysmal form of the arrhythmia. have revealed a
much better sinus rhythm control with the catheter
ablation than with antiarrhythmic drug therapy, at
least in the short-term (4,5). However, long-term
analyses tend to show the opposite with a higher rate
of successful maintenance of sinus rhythm on antiar-
rhythmic agents and a substantial number of late AF
relapse after the intervention (6).
Given that one of the main reasons for rhythm
control with catheter ablation is the prevention of
the most feared AF complication, cerebral thrombo-
embolism, what do the facts show in this respect?
The updated worldwide surveys estimate that cathe-
ter ablation per se may be responsible for symptom-
atic cerebral thromboembolism in 0.23% cases for
stroke to 0.71% cases for transient ischaemic attacks
(7). However, it is increasingly recognised that
highly symptomatic and often immediately disabling
cerebral events represent only the tip of the iceberg
of all AF-related cerebral thromboembolism. In addi-
tion to clinically evident strokes and transient ischae-
mic attacks, many patients suffer recurrent ‘silent’
cerebral embolism.
The phenomenon of ‘silent’ cerebral embolism is
well described for patients with permanent AF, par-
ticularly in the context of progressive AF-related
dementia. Various studies have demonstrated cogni-
tive impairment in subjects with long-standing AF,
presumably due to recurrent release of microthrombi
from dysfunctional atria (8–10). In fact, such micro-
thrombi correlate with symptomatic cerebral infarcts
in patients with AF perhaps indicating the presence
of a ‘thromboembolic continuum’ with the bigger
thrombi leading to the symptomatic cerebrovascular
events (11). Whilst postprocedural thromboembo-
lism is well documented for different cardiovascular
interventions, it is only becoming more apparent
that the problem is highly relevant to the procedures
of the catheter ablation (12,13).
Although the incidence of the postprocedural
‘silent’ thromboembolism is not precisely known, a
recent report found that 11% of patients with AF
suffered new postprocedural (i.e. after externally irri-
gated radiofrequency ablation) cerebral embolism
within 1 day as revealed by diffusion-weighted mag-
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